U.S. Markets close in 3 hrs 3 mins

Pulmatrix selected to present company profile at the 2018 Respiratory Innovation Summit in San Diego

Company will also present pre-clinical data on RV1162 (PUR1800) at the affiliated American Thoracic Society 2018 International Conference in San Diego

LEXINGTON, Mass., May 17, 2018 /PRNewswire/ -- Pulmatrix, Inc. (PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases has been selected to present at the 2018 Respiratory Innovation Summit at the Manchester Grand Hyatt in San Diego.  Pulmatrix CEO Robert Clarke, PhD, will present the company profile in the Drug Delivery & Diagnostics Company Showcase at 10:50AM PDT on May 19, 2018.

Pulmatrix logo (PRNewsFoto/Pulmatrix, Inc.)

The day long Respiratory Innovation Summit is intended to engage top Investors, Industry Leaders, Innovators, and Key Opinion Leaders to discuss key topics in the translation of concepts to therapeutics, diagnostics, smart tools, and devices for treatment of pulmonary diseases.  "We are pleased that Pulmatrix was selected to present at this prestigious meeting in advance of the 2018 American Thoracic Society conference and look forward to the opportunity to present our technology platform and our product pipeline to this audience," said Robert W. Clarke, Ph.D., Chief Executive Officer of Pulmatrix.

At 11:15AM PDT on May 22, 2018, Aidan Curran, PhD and Senior Director, Research at Pulmatrix will present pre-clinical data on RV1162 (PUR1800) in an abstract entitled "The Effect of PUR1800, a Novel Narrow Spectrum Kinase Inhibitor, on Viral Replication and Viral-Induced Inflammation in Primary Human Airway Cells" at the American Thoracic Society 2018 International Conference. 

About Pulmatrix
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis ("ABPA"), and PUR1800, a narrow spectrum kinase inhibitor for patients with obstructive lung diseases including asthma and chronic obstructive pulmonary disease ("COPD"). In addition, Pulmatrix has partnered with Vectura Group plc to develop Pulmatrix's drug candidate, PUR0200, for COPD for the U.S. market. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

FORWARD-LOOKING STATEMENTS
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that such statements involve risks and uncertainties that may materially affect the Company's results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's filings with the Securities and Exchange Commission, including its annual report on Form 10-K filed by the Company with the Securities and Exchange Commission on March 13, 2018, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact               


Robert Clarke, CEO              

William Duke, CFO       

(781) 357-2333                     

(781) 357-2333  

rclarke@pulmatrix.com    

wduke@pulmatrix.com

 

Cision

View original content with multimedia:http://www.prnewswire.com/news-releases/pulmatrix-selected-to-present-company-profile-at-the-2018-respiratory-innovation-summit-in-san-diego-300650043.html